Evidence map›Paper›PMID 40205399›Full record

ArticleBMC urology2025

Comparison of hyperthermic intravesical chemotherapy using pirarubicin and Bacillus Calmette-Guérin in the treatment of patients with high-risk non-muscle-invasive bladder carcinoma: a retrospective study.

Zhilong Huang, Shibo Huang, Eran Wu, Qinghua He, Xuedong Wei, Weiming Liang

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhilong Huang *The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, 124 Yuejin Road, Liuzhou, 545000, Guangxi Province, China.
Shibo Huang *The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, 124 Yuejin Road, Liuzhou, 545000, Guangxi Province, China.
Eran WuThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, 124 Yuejin Road, Liuzhou, 545000, Guangxi Province, China.
Qinghua HeThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, 124 Yuejin Road, Liuzhou, 545000, Guangxi Province, China.
Xuedong WeiThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, 124 Yuejin Road, Liuzhou, 545000, Guangxi Province, China.
Weiming LiangThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, 124 Yuejin Road, Liuzhou, 545000, Guangxi Province, China. liangwm22@icloud.com.

Funding

Guangxi Health Commission Z-B20220927the Guangxi Natural Science Foundation 2025GXNSFHA069019the Scientific Research Foundation of Guangxi University of Science and Technology 20Z13
6 · The paper itself

Abstract

purposeTo evaluate and compare the effectiveness and safety of hyperthermic intravesical chemotherapy (HIVEC) utilizing pirarubicin (THP) and Bacillus Calmette-Guérin (BCG) in the treatment of individuals diagnosed with high-risk non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND

methodsThis study was a retrospective study that combined a review of medical records with an outcomes management database. A total of 48 patients who received HIVEC with THP and 43 patients who received BCG treatment following transurethral resection of bladder tumors (TURBT) were found between January 2017 and December 2020. Recurrence-free survival (RFS), progression-free survival (PFS), overall survival (OS) and adverse events (AEs) were evaluated.

resultsThe baseline features of the HIVEC group (n = 48) and the BCG group (n = 43) were evenly matched. The median duration of follow-up was 61.0 ± 14.5 months. RFS at 1, 2, 3, 4, and 5 years of the BCG group and the HIVEC group were (90.76%, 76.54%, 58.07%, 51.14%, 45.05% vs. 98.04%, 79.53%, 62.46%, 55.93%, 50.03%, p = 0.58). PFS at 1, 2, 3, 4, and 5 years were (97.77%, 85.85%, 81.01%, 74.26%, 67.36% vs. 100.00%, 89.57%, 83.05%, 76.68%, 73.68%, p = 0.53). OS at 1, 2, 3, 4, and 5 years were (100.00%, 100.00%, 90.64%, 88.47%, 83.43% vs. 100.00%,100.00%,97.81%, 96.08%, 90.40%, p = 0.45). The overall incidence and severity of AEs related to the therapy were comparable in both groups.

conclusionHIVEC with THP offered a satisfactory safety profile and similar effectiveness to BCG. Our findings suggest that it may be regarded as a viable supplementary treatment for high-risk NMIBC patients when there is a shortage of BCG.

Indexed as

Adjuvants, ImmunologicAntineoplastic AgentsBCG VaccineDoxorubicinHyperthermia, InducedUrinary Bladder NeoplasmsAdministration, IntravesicalAgedFemaleHumansMaleMiddle AgedNeoplasm InvasivenessRetrospective StudiesAdjuvants, ImmunologicAntineoplastic AgentsBCG VaccineDoxorubicinpirarubicinHyperthermiaHyperthermic intravesical chemotherapy (HIVEC)Intravesical chemotherapyNon-muscle-invasive bladder cancer (NMIBC)Pirarubicin (THP)

Identifiers

PMID40205399
PMCPMC11980134

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.